# A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB

> **NCT07095855** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhimeng Biopharma, Inc.** · enrollment: 1300 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ZM-H1505R 100mg
- **OTHER:** ZM-H1505R Placebo
- **COMBINATION_PRODUCT:** NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments

## Key facts

- **NCT ID:** NCT07095855
- **Lead sponsor:** Shanghai Zhimeng Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2028-01
- **Final completion:** 2030-01
- **Target enrollment:** 1300 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07095855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07095855, "A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07095855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*